Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Br J Cancer. 2024 Aug;131(3):611. doi: 10.1038/s41416-024-02769-6.
No abstract available

Publication types

  • Published Erratum